My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.14 -0.51 (-1.20%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock ↗

Today 5:01 EST

Exelixis (EXEL) is a GARP stock with strong earnings growth, a reasonable valuation, and a debt-free balance sheet.

Via Chartmill

S&P 500 Surges as Congress Nears End to Protracted Government Shutdown

November 10, 2025

Washington D.C. – November 10, 2025 – Global financial markets are breathing a collective sigh of relief today as the S&P 500 index experiences a significant uplift, signaling investor optimism over...

Via MarketMinute

Global Markets Rally on Hopes for US Government Shutdown Resolution

November 10, 2025

Global financial markets are breathing a collective sigh of relief, with stock futures surging as investors cling to cautious optimism for an imminent end to the protracted United States government...

Via MarketMinute

Topics Bonds Economy Government

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Preview: Exelixis's Earnings ↗

November 03, 2025

Via Benzinga

17 Analysts Have This To Say About Exelixis ↗

September 17, 2025

Via Benzinga

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

What's Driving the Market Sentiment Around Exelixis Inc? ↗

October 30, 2025

Via Benzinga

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗

October 28, 2025

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer.

Via Benzinga

Peering Into Exelixis's Recent Short Interest ↗

September 15, 2025

Via Benzinga

Is the Market Bullish or Bearish on Exelixis? ↗

August 26, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) Represents an Affordable Growth Opportunity ↗

October 28, 2025

Discover EXELIXIS (EXEL), an affordable growth stock with strong profitability, sound finances, and a compelling valuation in the biotech sector.

Via Chartmill

This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

October 21, 2025

Via Benzinga

Top 3 Health Care Stocks You'll Regret Missing In October ↗

October 21, 2025

Via Benzinga

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗

October 20, 2025

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.

Via Benzinga

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

October 20, 2025

Via Benzinga

The Ultimate Biotech Stock to Buy With $50 Right Now ↗

October 14, 2025

This innovative drugmaker still has plenty of upside potential.

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening ↗

October 07, 2025

Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock ↗

October 04, 2025

Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector.

Via Chartmill

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗

September 30, 2025

Both should have significant catalysts by the end of the decade.

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Undervalued Stock with Strong Fundamentals ↗

September 15, 2025

EXELIXIS (EXEL) emerges as a top value stock with strong fundamentals: undervalued, zero debt, high profitability, and solid growth in the biotech sector.

Via Chartmill

Exelixis Inc (NASDAQ:EXEL) Embodies the Affordable Growth Investment Strategy ↗

September 13, 2025

Exelixis (EXEL) offers affordable growth with strong oncology revenue, high profitability, a robust balance sheet, and attractive valuation metrics.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗

August 25, 2025

Exelixis (EXEL) is a strong value investing candidate, trading below intrinsic value with a solid financial profile, high profitability, and strong growth prospects.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Growth at a Reasonable Price (GARP) Stock ↗

August 22, 2025

EXELIXIS INC (EXEL) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

Exelixis Inc (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Setup ↗

August 16, 2025

Exelixis (EXEL) is a strong growth stock with solid fundamentals—17.5% revenue growth, high profitability, and no debt—plus a bullish technical setup, signaling a potential breakout opportunity.

Via Chartmill

The Analyst Verdict: Exelixis In The Eyes Of 19 Experts ↗

August 12, 2025

Via Benzinga

Exelixis EXEL Q2 2025 Earnings Call Transcript ↗

August 04, 2025

Via The Motley Fool

Topics Earnings

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? ↗

August 03, 2025

Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL): A Strong Value Investment with Undervalued Potential and Solid Fundamentals ↗

July 30, 2025

EXELIXIS (EXEL) is a top value stock with strong fundamentals—undervalued P/E, zero debt, high profitability, and solid growth. Ideal for value investors seeking quality at a discount.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.